Due to the lack of a protective vaccine, there is a need to develop topical microbicides to prevent human immunodeficiency virus type 1 (HIV-1) sexual transmission. The envelope glycoprotein (Env) of HIV-1 is key to viral entry of susceptible target cells, and therefore a major target for the design of vaccines and antiviral drugs. The extracellular Env gp120 is a heavily glycosylated protein, with ,18-33 potential N-linked glycosylation sites (PNLGs) being found in the gp120 sequences (François & Balzarini, 2012; Leonard et al., 1990) . The carbohydrate-binding agents (CBAs) griffithsin (GRFT) and cyanovirin-N (CV-N) have been widely investigated as anti-HIV agents. Both can inhibit HIV-1 at nanomolar concentrations (Bewley, 2001; Boyd et al., 1997; Mori et al., 2005; Ziółkowska et al., 2006) and CV-N has been shown to prevent simian immunodeficiency virus/HIV infection in macaques (Tsai et al., 2003 (Tsai et al., , 2004 .
Despite the high potency of CBAs, HIV-1 can evolve resistance to CBAs with deletions of high-mannose and complex-type glycan residues mainly occurring in the C2-C4 regions of gp120 (Alexandre et al., 2013; Balzarini et al., 2006; Hu et al., 2007) . However, the frequency of natural resistance to CBAs in transmitted/founder (T/F) viruses has not been characterized. This may have particular importance when considering the development of CBAs for use as topical microbicides to prevent HIV-1 sexual transmission. T/F viruses were isolated very early after transmission and are thought to be more physiologically relevant than those isolated during chronic infection (Keele et al., 2008) . Keele et al. (2008) found that 76 % of HIV-1-infected subjects were infected by a single T/F virus. T/F viruses normally have shorter and less glycosylated V1-V4 domains than chronic HIV-1 (Haaland et al., 2009) . In addition, the glycosylation patterns on T/F Envs are different from those on chronic Envs, with the former having more high-mannose glycans (Go et al., 2011) . Whether the high level of high-mannose glycans on T/F Envs confers different sensitivity to CBAs remains unknown.
Given the importance of T/F viruses in HIV-1 transmission, it is crucial to understand the sensitivity of different T/F HIV-1 to CBAs. To this end, we investigated the sensitivity of 20 subtype B T/F Envs (Keele et al., 2008) to three CBAs, i.e. GRFT, CV-N, and Galanthus nivalis agglutinin (GNA) (Sigma) (Balzarini et al., 1991; Van Damme et al., 1987) , by a well-established neutralization assay (Huang et al., 2011) using pseudotyped viruses (Hu et al., 2007) to infect TZM-bl cells. The tested T/F Envs showed different sensitivity to the three CBAs, with IC 50 values ranging from 0.006¡0.0003 to .10 nM for GRFT, from 0.6¡0.2 to 28.9¡2.9 nM for CV-N and from 1.3¡0.2 to .500 nM for GNA (Table 1 ). The majority of T/F Envs were extremely sensitive to GRFT, with IC 50 values ,1 nM, two of which were only 6 pM. Nevertheless, two T/F Envs were not inhibited even at concentrations .10 nM. In contrast, CV-N was able to inhibit all the T/F Envs and the IC 50 values varied less significantly than those of GRFT, with the highest IC 50 being ,50-fold the lowest IC 50 . GNA was the most ineffective CBA against T/F Envs. Only seven out of 20 T/F Envs were inhibited at concentrations ,100 nM, whereas inhibition of six T/F Envs could not be achieved even at 500 nM. Amongst these T/F Envs, 700010058.A4.4375 was extremely sensitive to all the three CBAs, with IC 50 values of 0.006¡0.0003 nM for GRFT, 0.6¡0.2 nM for CV-N and 1.3¡0.2 nM for GNA. In contrast, 700010040.C9.4520 and 62615_03.P4.3964 showed resistance to GRFT and GNA, with IC 50 values of .10 nM for GRFT and .500 nM for GNA, and were also less sensitive to CV-N, with IC 50 values of 16.2¡4.3 and 28.9¡2.9 nM, respectively.
The number and position of PNLGs could influence the susceptibility of T/F Envs to CBAs. Several studies showed that glycosylation sites on HIV-1 gp120 were mutated to non-glycosylation sites when the virus was cultured under escalating concentrations of CBAs (Balzarini et al., 2006; Hu et al., 2007) . We analysed the gp120 sequences of these T/F Envs to identify PNLGs according to the glycosylation pattern of HXB2 gp120 (Leonard et al., 1990) . There was no clear correlation between the number of PNLGs and CBA sensitivity (Table S1 , available in the online Supplementary Material). However, the numbers of PNLGs and potential high-mannose glycan sites of 700010040.C9.4520 (21 and 6, respectively) and 62615_03. P4.3964 (24 and 7, respectively) that demonstrated significant CBA resistance were less than those of the CBA-sensitive clone 700010058.A4.4375 (25 and 10, respectively).
We subsequently compared the PNLGs in the variable regions as described by Shaw & Zhang (2013) and the conserved regions as described previously by us (Huang et al., 2011) . As there are high sequence variations in the variable regions of gp120 amongst different HIV-1 isolates, we compared the number of PNLGs in the V1-V5 regions of the three T/F env clones. We found no consistent difference in the V1 and the V3-V5 domains amongst the three T/F env genes. However, there is one PNLG in the V2 domain of both 700010040.C9.4520 and 62615_03.P4.3964, and two in that of 700010058.A4.4375, whereas 16 out of the other 17 T/F env clones have at least two PNLGs in the V2 region (Fig. 1b) . A previous study showed that a single or multiple deglycosylation in the V1-V2 region could render HIV-1 NL4-3 more sensitive to CBAs (Auwerx et al., 2008) , implying that the number of PNLGs in the V2 domain may influence the sensitivity of T/F Envs to CBAs. Given that the number (Fig. 1d) . In contrast, all GRFT-sensitive T/F Envs have the two PNLGs (Fig. 1c) . In our previous study, we revealed that deglycosylation at 295 or 448 confers GRFT resistance to HIV-1 (Huang et al., 2011) . Whether similar findings can be reproduced with T/F Envs needs to be addressed. We constructed deglycosylation mutants at 295 or 448 of 700010058.A4.4375, and glycan-retaining mutants at (Fig. 2b , Table S2 ) and 115-fold (Fig. 2c, Table S2 ), respectively. Although dual deglycosylation at both 295 and 448 did not render 700010058.A4.4375 fully resistant to GRFT, the sensitivity decreased .33-fold (Fig. 2a, Table S2 ). On the contrary, deglycosylation or glycan-retaining mutation at 295 or 448 had little impact on the sensitivity of Env to CV-N and GNA (Table S2 ).
To understand the association between T/F Env glycans and the sensitivity to CV-N and GNA, we constructed a series of mutants of 700010058.A4.4375 with single deglycosylation at each PNLG in the conserved domains. We found that a much higher concentration of CV-N or GNA was required to inhibit the infection of the mutant with deglycosylation at 339 (Fig. 2d, f) . In agreement, the IC 50 of CV-N against 700010040.C9.4520 decreased to 4.7¡1.5 nM when a glycan at 339 was introduced (Fig. 2e , Table S2 ). Considering that the three tested CBAs likely share common glycans on Env (Alexandre et al., 2013; Balzarini et al., 2005 Balzarini et al., , 2006 , we produced a mutant of 700010058.A4.4375 by removing the three potential glycans at 295, 339 and 448. The triple deglycosylation mutant was less sensitive to CV-N than the mutant with a single or dual deglycosylation at the three PNLGs, whereas the sensitivity to GNA was similar to that of the single glycan mutant at 339. Of note, deglycosylation at 295, 339 and 448 rendered 700010058.A4.4375 largely resistant to GRFT, with an IC 50 .10 nM which was 50-fold higher than that of the dual deglycosylation mutant at 295 and 448, and .1666-fold higher than that of the parental clone (Fig. 2 , Table S2 ). A similar pattern of inhibition profiles was confirmed in PBMCs (Fig. S2) . We also compared the infection and the expression of T/F Env mutants, revealing no apparent difference compared with those of WT Env (Fig. S3) . Taken together, the data indicate that the sensitivity of T/F Env to GRFT is mainly determined by glycans at 295, 339 and 448.
Considering that sexual transmission of HIV-1 is often caused by a single T/F virus and that CBAs are potential topical microbicides against HIV-1 mucosal infection, it is important to determine the sensitivity profiles of T/F HIV-1 to different CBAs. We found that, compared with chronic isolates (Alexandre et al., 2010; Huang et al., 2011) , the majority of T/F Envs appeared to be more sensitive to GRFT, but less sensitive to GNA. Amongst the three different CBAs, T/F Envs were extremely sensitive to GRFT, with the IC 50 values of two T/F Envs being 6 pM. One possible reason is that GRFT is a small protein (Mori et al., 2005) and functions as a domain-swapped dimer with six carbohydrate-binding sites (Zió łkowska et al., 2006) showed that deglycosylation at 295 and 448 or 234 on subtype C HIV-1 could confer GRFT resistance (Alexandre et al., 2010; Huang et al., 2011) , suggesting that, in comparison with other CBAs, GRFT resistance may be easier to achieve by HIV-1. As with GRFT, CV-N also forms into a domain-swapped dimer, but has four carbohydrate-binding sites. We found that all of the 20 T/F Envs were sensitive to CV-N and the highest IC 50 was ,50-fold higher than the lowest IC 50 , demonstrating a smaller range of variation compared with those of GRFT and GNA. As for GNA, very high concentrations were required to inhibit the infection of the 20 T/F Envs. GNA is a tetrameric plant lectin with a molecular mass of 50 kDa (Van Damme et al., 1987) . The large mass of GNA likely makes it difficult to gain access to the carbohydrates on Env because of steric hindrance. Therefore, small CBAs with multiple carbohydrate-binding sites, such as CV-N and GRFT, are more potent in terms of microbicide development. Nevertheless, CV-N appeared to be toxic at high concentrations and showed mitogenic activity in PBMCs (Balzarini et al., 2006; Huskens et al., 2008) . The side-effects of CBAs warrant further investigation. In addition, although the majority of T/F Envs were sensitive to the tested CBAs in our study, several clones demonstrated resistance at different degrees. More experiments are needed when considering the use of CBAs as topical microbicides.
In summary, we identified two T/F Envs, 700010040.C9.4520 and 62615_03.P4.3964, that showed significant resistance to the three CBAs, and 700010058.A4.4375 which was extremely sensitive to the CBAs. Sequence analyses and mutagenesis studies indicated that the total number of PNLGs and the number of PNLGs in the V2 region had little influence on the sensitivity of T/F Envs to CBAs, suggesting that the location of N-linked glycans likely plays an important role. In agreement, glycans at 295, 339 and 448 in the C2-C4 regions appeared to determine the sensitivity of T/F Envs to GRFT and to CV-N, although to a lesser extent. We previously proposed a model (Huang et al., 2011) in which glycans at 295 and 448 on the 'sugar tower' bind to GRFT and the other glycan at 332 functions as a scaffold to support this structure. In agreement, our findings in the current study support this model, revealing the involvement of 295, 339 and 448 in GRFT binding. In general, the number of 295, 339 and 448 glycans appeared to be associated with GRFT sensitivity (Fig. S4 , Table S1 ), and T/F Envs with all the three potential high-mannose glycans had low IC 50 values. Of interest, 339 also appeared to play a role in GRFT binding. One explanation is that glycan at 339 is close to that at 332 and may be involved in the scaffold. Although the glycan site at 234 is not present in the sequence of 700010040.C9.4520, we found no evidence of its association with the resistance of 700010040.C9.4520 to GRFT, because several other T/F Envs that were sensitive to GRFT also do not have the potential 234 glycan. However, we have not identified specific glycans that together determine the sensitivity of T/F Envs to CV-N or GNA, apart from that deglycosylation at 339 decreased the sensitivity of Envs to CV-N and GNA. glycan insertion at 339, but did not show different sensitivity to GNA. This is likely because 700010040.C9.4520 is too resistant to GNA and consequently the addition of a glycan at 339 only marginally increased its sensitivity. Balzarini et al. (2005 Balzarini et al. ( , 2006 found that HIV-1 isolates showing resistance to CV-N were also cross-resistant to GNA and vice versa. Moreover, GRFT binding to gp120 could be partially blocked by CV-N (Mori et al., 2005) . Taken together with the observation that the three CBAs preferentially bind to high-mannose glycans, it is probable that glycans at certain sites are involved in the binding of Envs to all the three CBAs. In agreement, we found that the mutant of 700010058.A4.4375 with triple deglycosylation at 295, 339 and 448 showed decreased sensitivity not only to GRFT, but also to CV-N. However, this mutant still could be inhibited by CV-N. As for GNA, there was little difference in IC 50 either between 700010058.A4.4375 with triple deglycosylation and individual deglycosylation at 339 or between WT Env and the mutant with dual deglycosylation at 295 and 448, indicating that only the glycan at 339 is involved in the binding of GNA to Env. Our results together imply that the three tested CBAs share some common glycans on Env.
In conclusion, we have identified specific residues of T/F Envs that are associated with CBA sensitivity. To our knowledge, this is the first study addressing the sensitivity of T/F HIV-1 to CBAs.
